CME Group (NASDAQ:CME) PT Raised to $219.00

CME Group (NASDAQ:CME) had its price target increased by Barclays from $209.00 to $219.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the financial services provider’s stock. Barclays‘s price target suggests a potential downside of 1.21% from the stock’s previous close.

A number of other analysts also recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on CME Group from $187.00 to $191.00 and gave the stock an “underweight” rating in a research report on Thursday, July 25th. Piper Sandler restated an “overweight” rating and issued a $225.00 target price on shares of CME Group in a research report on Tuesday, August 20th. Keefe, Bruyette & Woods boosted their target price on CME Group from $212.00 to $213.00 and gave the stock a “market perform” rating in a research report on Thursday, July 25th. Citigroup boosted their target price on CME Group from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. Finally, TD Cowen began coverage on CME Group in a research report on Thursday, September 26th. They issued a “hold” rating and a $221.00 target price for the company. Four analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $217.71.

CME Group Stock Down 0.0 %

Shares of NASDAQ CME opened at $221.68 on Monday. CME Group has a 12 month low of $190.70 and a 12 month high of $226.78. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $79.82 billion, a price-to-earnings ratio of 25.22, a PEG ratio of 8.74 and a beta of 0.55. The business has a 50-day moving average of $212.63 and a 200-day moving average of $207.68.

CME Group (NASDAQ:CME) last issued its quarterly earnings data on Wednesday, July 24th. The financial services provider reported $2.56 EPS for the quarter, topping the consensus estimate of $2.53 by $0.03. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the previous year, the firm earned $2.30 earnings per share. CME Group’s revenue was up 12.7% on a year-over-year basis. Sell-side analysts expect that CME Group will post 9.94 earnings per share for the current fiscal year.

Insider Activity at CME Group

In related news, Director Bryan T. Durkin sold 7,593 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the completion of the transaction, the director now owns 55,607 shares in the company, valued at $11,932,706.13. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Bryan T. Durkin sold 7,593 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $214.59, for a total value of $1,629,381.87. Following the sale, the director now directly owns 55,607 shares of the company’s stock, valued at $11,932,706.13. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Lynne Fitzpatrick sold 754 shares of the company’s stock in a transaction on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total value of $163,610.46. Following the completion of the sale, the chief financial officer now directly owns 13,261 shares in the company, valued at approximately $2,877,504.39. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CME Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new stake in shares of CME Group in the first quarter worth $28,000. Y.D. More Investments Ltd purchased a new stake in shares of CME Group in the second quarter worth $36,000. McClarren Financial Advisors Inc. boosted its position in shares of CME Group by 66.1% during the second quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock valued at $39,000 after buying an additional 78 shares during the last quarter. Asset Dedication LLC boosted its position in shares of CME Group by 515.2% during the second quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock valued at $40,000 after buying an additional 170 shares during the last quarter. Finally, Rise Advisors LLC purchased a new stake in shares of CME Group during the first quarter valued at $41,000. 87.75% of the stock is owned by hedge funds and other institutional investors.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.